Johnson & Johnson (JNJ) Shares Sold by Rathbone Brothers plc
Rathbone Brothers plc decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 244,310 shares of the company’s stock after selling 7,805 shares during the quarter. Johnson & Johnson accounts for 1.4% of Rathbone Brothers plc’s holdings, making the stock its 19th largest position. Rathbone Brothers plc’s holdings in Johnson & Johnson were worth $34,135,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of JNJ. Harding Loevner LP bought a new stake in Johnson & Johnson in the second quarter valued at about $106,000. Mountain Capital Investment Advisors Inc bought a new stake in Johnson & Johnson in the second quarter valued at about $124,000. Cerebellum GP LLC bought a new stake in Johnson & Johnson in the fourth quarter valued at about $166,000. Lenox Wealth Management Inc. increased its stake in Johnson & Johnson by 1.7% in the second quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock valued at $193,000 after acquiring an additional 24 shares during the period. Finally, Jentner Corp bought a new stake in Johnson & Johnson in the fourth quarter valued at about $209,000. Institutional investors own 67.23% of the company’s stock.
In other news, VP Paulus Stoffels sold 155,342 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the transaction, the vice president now directly owns 357,906 shares in the company, valued at $46,477,673.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.22% of the stock is currently owned by corporate insiders.
Shares of JNJ stock opened at $131.76 on Tuesday. Johnson & Johnson has a 1 year low of $120.95 and a 1 year high of $148.32. The company has a market cap of $350,440.66, a PE ratio of 18.05, a P/E/G ratio of 2.08 and a beta of 0.74. The company has a current ratio of 1.41, a quick ratio of 1.12 and a debt-to-equity ratio of 0.51.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.72 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. The company had revenue of $20.20 billion for the quarter, compared to analyst estimates of $20.08 billion. During the same period in the prior year, the business earned $1.58 earnings per share. Johnson & Johnson’s quarterly revenue was up 11.5% on a year-over-year basis. research analysts predict that Johnson & Johnson will post 8.11 EPS for the current year.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.